503 results about "Neurologic disease" patented technology

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurological disease associated with repeat expansions and / or RAN protein accumulation, reducing the level of one or more repeat associated non-AUG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and / or biological sample. Exemplary diseases associated with repeat expansions include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, myotonic dystrophy type 1, myotonic dystrophy type 2, spinocerebellar ataxia, Alzheimer's disease, Huntington's disease, Fragile X Tremor Ataxia Syndrome, and Fragile XE syndrome.

The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and / or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson Disease or related condition resulting from a deficiency in the quantity and / or function of GBA gene product or associated with decreased expression or protein levels of GCase protein.

Disclosed herein is a method of safely treating a nervous system condition with a combination of dextromethorphan and bupropion. This method is intended for patients having a neurological condition or a psychiatric condition, such as major depressive disorder, and a CYP2D6 poor metabolizer genotype or a CYP2D6 poor metabolizer phenotype.

The invention discloses a disease early warning method and device, and relates to the technical field of disease early warning, the method utilizes rich target disease related knowledge in clinical examination result data, and through a cross-modal knowledge distillation method, knowledge learned by a multi-modal teacher model is transferred to a student model only accessing a man-machine interaction mode, so that the disease early warning is realized. The disease early warning capability of the man-machine interaction student model is improved. Knowledge highly related to the target disease in the clinical examination result data can be migrated to the man-machine interaction data, so that a more accurate early warning result can be obtained under the condition that only the man-machine interaction data is applicable. A low-cost and low-burden nervous system disease early warning mode based on human-computer interaction data is realized, and early recognition and long-term monitoring can be performed on large-scale crowds with onset risks.

Provided are deuterated analogs of MDMA, including deuterated empathogens. In some embodiments, such compounds are monoamine releasers or inhibit monoamine transporters. In some aspects, features of the compounds provide stability, such as metabolic stability, and efficacy. Also provided are methods for the preparation of deuterated empathogens and pharmaceutical compositions comprising the same. Methods of using the deuterated empathogens, alone or in combination with other therapeutic agents, are provided. In some embodiments, deuterated empathogens are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders.

An apparatus includes an input unit, a processing unit, and an output unit. The input unit is configured to provide the processing unit with at least one diffusion magnetic resonance imaging dMRI image of a patient's brain. The processing unit is configured to: 1) determine an estimate of an orientation of neurons at each voxel in the dMRI image; 2) determine a plurality of fiber tracts in the at least one dMRI image; 3) select a plurality of voxels along at least one fiber tract of the plurality of fiber tracts; and 4) determine a neurological disease classification.

Disclosed are methods of treating a subject with a neurological disease associated with a splicing defect caused by TDP-43 proteinopathies, comprising administering to said subject an agent to increase expression levels and / or stability of hnRNP L, thereby attenuating and / or repairing the splicing defect. The disclosure also relates to nucleic acids targeting heterogeneous nuclear ribonucleoprotein L (hnRNP L), and their use.

Novel compounds such as DHMP maintain DHM features and pharmacological activities with increased potency and efficacy, improved water solubility, enhanced bioavailability, increased permeability to the blood brain barrier (BBB), and increased stability. Because DHMP retains the therapeutic activities of DHM and has properties that improve its bioavailability, it can be used as a therapeutic agent for treating Alzheimer's disease-related diseases (ADRD) including Alzheimer's disease (AD), Vascular Dementia, Frontotemporal Dementia (FTD), Mixed Dementia as well as neurodegeneration such as Parkinson's disease. Administration of these compounds result in beneficial pathological changes including reduction of Aꞵ and Tau, improvement of neuroinflammation, reduction of cognitive / memory deficits, as well as improvement of anxiety, depression, and aggression. The disclosed DHM derivatives can also be used to treat sleep disorders, neurological disorders such as PTSD, Autism, Epilepsy / Seizures, and Alcohol Use Disorders (AUD), fetal alcohol syndrome (FAD), substance addictions, and cancers.

A method for classifying neurological disease status is described. The method includes acquiring, by a data preprocessor logic, patient image data. The method further includes generating, by a trained artificial neural network (ANN), a classification output based, at least in part, on the patient image data. The classification output corresponds to a neurological disease status of the patient. The trained ANN is trained based, at least in part, on longitudinal source data.

An apparatus and method for aiding in the detection of dementia, concussion, other neurologic conditions, retinal, and optic nerve conditions. The apparatus enables the diffusion coefficient of the tissue to be ascertained and studied by directing the light from a laser or other coherent light source at the patient's retina, optic nerve or choroid and measuring the fluctuations in the intensity of the back-scattered light caused by the movement of light scatterers in the tissue. By comparing the measurements to a normal database, or to the subject's previous measurement, in combination with an eye examination and OCT image / measurement the changes caused by the disease and the effectiveness of therapy can be ascertained. The disclosed apparatus allows the incident and detection optics to be attached to ophthalmic devices typically used in ophthalmologic care. Also, where both the incident laser fiber optic and the detection fiber optic are directly connected to goggles, one or more or all of the above-described mirrors may not be necessary, as both fiber optics are preferably directly directed into the eye.

The present disclosure provides materials and methods for delivery of a transgene to target cells. The regulatory elements, transgenes, and expression vectors are useful in, e.g., expressing a transgene in CNS cells that results in an improvement in at least one symptom related to a neurological disease or disorder, including epilepsy disorders, such as refractory epilepsy.

Disclosed herein are UNC13A oligonucleotides with one or more spacers or without a spacer. In various embodiments, UNC13A oligonucleotides with spacer(s) reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

A combined neuromodulation and / or neurostimulation system for mitigating locomotor deficits of / or neuronal disorders, especially Parkinson's disease, said system comprises: at least one Deep Brain Stimulation System for providing Deep Brain Stimulation to brain tissue of a subject, at least one control unit, configured and adapted to provide stimulation data, at least one stimulation unit, operatively connected to the at least one control unit, the at least one stimulation unit being configured and adapted to deliver epidural electrical stimulation to the dorsal side of the spinal cord of said subject, and at least one implantable pulse generator, wherein the at least one stimulation unit includes one or more electrodes configured to be implanted epidurally, the one or more electrodes being operatively connected to the at least one IPG.

The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and / or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

The invention discloses a universal medical image auxiliary diagnosis system which comprises an ultra-low radioactivity imaging module which adopts a 3D CycleGAN network as a basic skeleton for PET image reconstruction; the epilepsy focus positioning analysis module is based on a self-adaptive medical image segmentation framework in deep learning; the user interface is used for providing a graphical operation interface and supporting multiple interaction modes so as to meet using habits of different doctors; and the data storage and management module is responsible for storage, backup and management of all medical image data and related information in the system, has data retrieval and query functions, and supports remote access and sharing. According to the universal medical image auxiliary diagnosis system, radiation exposure of a patient can be remarkably reduced, the accuracy and reliability of focus positioning can be improved, and powerful technical support is provided for diagnosis and treatment of nervous system diseases such as epilepsy.

Provided are TYK2 inhibitors of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. These compounds are useful, for example, in treating TYK2-mediated disorders, such as, autoimmune and inflammatory disorders, metabolic disorders, proliferative disorders, endocrine disorders, neurological disorders, allergic disorders, and disorders associated with transplantation.

The invention relates to psychoactive medicines including methylone, 2C-B, MBDB, their respective salts, metabolites, isomers, enantiomers, solvates, isotopologues and isotopomers, polymorphs, prodrugs and analogs (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

The present disclosure relates to compounds, pharmaceutical compositions, and methods of using the compounds and compositions to image reactive oxygen and nitrogen species (RONS). The disclosed compounds and pharmaceutical compositions can also be useful in treating diseases or disorders due to oxidative stress or otherwise based on RONS pathophysiology such as, for example, neurological diseases, cancer, cardiovascular diseases, and ischemia reperfusion injury (IRI). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

A non-invasive computer-aided system for classification of neurological disorders uses as input neuroimaging data, extracts morphological features from the neuroimaging data characteristic of each of a plurality of behavioral domains associated with the neurological disorder, and uses machine learning models to classify the severity of the disorder for each of the plurality of behavioral domains based on the extracted morphological features.

A system for analyzing a neurological and / or neurodegenerative disorder (ND) is disclosed. The system include an electrocardiogram (ECG) sensor and an inertial measurement unit (IMU) sensor to a subject; a processor; a memory that stores instructions. When executed by the processor, the instructions cause the processor to: gather ECG and IMU data for the subject; input the integrated ECG and IMU data to a first computational model and a second computational model; and infer a presence of the ND based on the first computational model, or a change in the ND based on the second computational model. A method for analyzing and ND is also disclosed.

A method for treating a neuropsychiatric or neurological disorder by inducing neurological response in a subject, the method comprising: selecting a frequency for application of non-invasive brain stimulation to which a subject is to be exposed; exposing the subject to the non-invasive sensory stimulation at the selected frequency in a range of about 5-100 Hz.

The invention discloses a lipid composition, lipid nanoparticles, a preparation method of the lipid nanoparticles, a pharmaceutical composition, a pharmaceutical preparation and application. The lipid composition is prepared from a cationic lipid SM-102, a cationic lipid NT-O14B, cholesterol, distearoyl phosphatidylcholine (DSPC) and a phospholipid polyethylene glycol (PEG) derivative. The invention provides the lipid composition which can be applied to preparation of lipid nanoparticles for brain delivery, through optimal combination of specific lipid components, the efficiency of penetrating through the blood brain barrier during LNP drug delivery is improved, reliable technical support is provided for application of siRNA drugs in nervous system diseases, and the lipid composition has the application prospect of promoting treatment of the nervous system diseases.